Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities,
such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular …

Crohn's disease (CD) accounts for a variety of clinical manifestations or phenotypes that
stem from chronic inflammation in the gastrointestinal tract. Its worldwide incidence is …

Incidence of IBD is rising in parallel with overweight and obesity. Contrary to conventional
belief, about 15–40% of patients with IBD are obese, which might contribute to the …

Introduction Crohn's disease (CD) and ulcerative colitis (UC) have a progressive course
leading to hospitalisation and surgery. The ability of existing therapies to alter disease …

Background & Aims Monitoring serum concentrations of tumor necrosis factor antagonists in
patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also …

Psoriasis is an immune-mediated inflammatory disease, with a chronic relapsing-remitting
course, which affects 2–3% of the worldwide population. The progressive acquisitions of the …

Innate immune cells, particularly macrophages and epithelial cells, play a key role in
multiple layers of immune responses. Alarmins and pro-inflammatory cytokines from the IL …

Abstract Background and Aims Therapeutic drug monitoring [TDM] has proven to be
effective for optimising anti-tumour necrosis factor [TNF] therapy in inflammatory bowel …

Background Anti‐tumour necrosis factor‐alpha agents (anti‐TNF) are effective therapies for
the treatment of Crohn's disease (CD), but their comparative efficacy is unknown. Aim To …

The treatment of IBD with anti-TNF agents has substantially evolved since their first
introduction more than a decade ago. The robust efficacy witnessed in many patients has …